Patrick Weiss Sells 4,089 Shares of Twist Bioscience Corp (NASDAQ:TWST) Stock

Twist Bioscience Corp (NASDAQ:TWST) COO Patrick Weiss sold 4,089 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $22.29, for a total transaction of $91,143.81. Following the sale, the chief operating officer now directly owns 95,628 shares of the company’s stock, valued at approximately $2,131,548.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

TWST stock traded down $1.11 during mid-day trading on Thursday, reaching $21.80. 448,100 shares of the company traded hands, compared to its average volume of 446,487. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.28 and a quick ratio of 5.03. The company has a market capitalization of $761.99 million, a P/E ratio of -5.46 and a beta of 0.71. Twist Bioscience Corp has a 52-week low of $19.64 and a 52-week high of $35.95. The company has a fifty day moving average price of $23.17 and a 200-day moving average price of $25.68.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Wednesday, December 11th. The company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.12). The company had revenue of $15.74 million for the quarter, compared to analysts’ expectations of $14.08 million. Twist Bioscience had a negative net margin of 197.98% and a negative return on equity of 73.98%. As a group, analysts forecast that Twist Bioscience Corp will post -3.11 EPS for the current year.

A number of hedge funds have recently bought and sold shares of TWST. Wells Fargo & Company MN grew its holdings in Twist Bioscience by 145.8% during the 2nd quarter. Wells Fargo & Company MN now owns 12,428 shares of the company’s stock valued at $360,000 after buying an additional 7,372 shares in the last quarter. Bank of Montreal Can grew its holdings in Twist Bioscience by 87,550.0% during the 2nd quarter. Bank of Montreal Can now owns 1,753 shares of the company’s stock valued at $51,000 after buying an additional 1,751 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Twist Bioscience by 311.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 129,060 shares of the company’s stock valued at $3,745,000 after buying an additional 97,704 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Twist Bioscience by 262.9% during the second quarter. Bank of New York Mellon Corp now owns 68,693 shares of the company’s stock worth $1,993,000 after purchasing an additional 49,762 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Twist Bioscience during the second quarter worth about $928,000. 47.18% of the stock is owned by institutional investors and hedge funds.

TWST has been the subject of several recent analyst reports. ValuEngine raised shares of Twist Bioscience from a “hold” rating to a “buy” rating in a research report on Friday, December 27th. Zacks Investment Research cut Twist Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, October 5th.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Article: Why does a company issue an IPO?

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.